232 related articles for article (PubMed ID: 10140321)
1. Ganging up on the FDA.
Stone PH
Natl J (Wash); 1995 Feb; 27(7):410-4. PubMed ID: 10140321
[No Abstract] [Full Text] [Related]
2. FDA plan for statutory compliance. Notice of availability.
Fed Regist; 1998 Nov; 63(226):65000-40. PubMed ID: 10338873
[TBL] [Abstract][Full Text] [Related]
3. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
4. FDA embraces risk-management approach.
Fox JL
Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
[No Abstract] [Full Text] [Related]
5. Panel recommends independence, more resources for FDA.
Am J Hosp Pharm; 1991 Aug; 48(8):1632, 1639. PubMed ID: 1897535
[No Abstract] [Full Text] [Related]
6. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
7. Prescription for change: an interview with FDA Commissioner Dr. David Kessler.
Kessler D
Physician Assist; 1992 Jul; 16(7):61-2, 65, 68-70. PubMed ID: 10120389
[TBL] [Abstract][Full Text] [Related]
8. Knowledge is power: legislative control of drug industry trade secrets.
O'Reilly JT
Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981
[No Abstract] [Full Text] [Related]
9. Who would approve new drugs if there were no FDA?
Gatty B
Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
[No Abstract] [Full Text] [Related]
10. The Orphan Products Board of the Department of Health & Human Services.
Crooks GM
Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294
[No Abstract] [Full Text] [Related]
11. Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson.
Woodcock J
Drug Discov Today; 2004 Jul; 9(13):548-50. PubMed ID: 15203087
[TBL] [Abstract][Full Text] [Related]
12. The FDA Amendments Act: reauthorization of the FDA.
von Eschenbach AC
Food Drug Law J; 2008; 63(2):579-84. PubMed ID: 18561478
[No Abstract] [Full Text] [Related]
13. No time for doomsday.
Stetler CJ
Hosp Formul; 1975 May; 10(5):220-1, 225-6. PubMed ID: 10237838
[No Abstract] [Full Text] [Related]
14. Perspectives. Approval process a moving target in FDA reform hearings.
Rhein R
Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
[No Abstract] [Full Text] [Related]
15. Healthy people 2000 initiative.
Rheinstein PH
Am Fam Physician; 1992 Dec; 46(6):1829-32. PubMed ID: 1456200
[No Abstract] [Full Text] [Related]
16. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
17. What ails the FDA?
Jenny-Avital ER
N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
[No Abstract] [Full Text] [Related]
18. New FDA Commissioner sees challenges, opportunities.
Lewis C
FDA Consum; 2003; 37(1):9. PubMed ID: 12625298
[No Abstract] [Full Text] [Related]
19. Seven Former FDA Commissioners: The FDA Should Be An Independent Federal Agency.
Califf RM; Hamburg M; Henney JE; Kessler DA; McClellan M; von Eschenbach AC; Young F
Health Aff (Millwood); 2019 Jan; 38(1):84-86. PubMed ID: 30615515
[TBL] [Abstract][Full Text] [Related]
20. Leavitt: reforms will improve oversight and openness at FDA.
FDA Consum; 2005; 39(3):37. PubMed ID: 16127819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
